Entrada Therapeutics' Next-Generation Duchenne Muscular Dystrophy Drug Fails Early Study

Entrada Therapeutics' next-generation therapy for Duchenne muscular dystrophy failed in an early clinical study, marking a setback in the competitive race to develop improved exon-skipping drugs. These treatments help patients with certain mutations produce shortened but functional dystrophin, the protein missing in Duchenne muscular dystrophy. Sarepta Therapeutics developed and gained approval for the first exon-skipping drug in 2016, though it had only marginal effects on protein production.

Entrada trial failure

• ▪Entrada Therapeutics' next-generation drug for Duchenne muscular dystrophy disappointed in an early trial.
• ▪Entrada Therapeutics' trial failure raised questions about the company's competitiveness in an increasingly crowded field of Duchenne muscular dystrophy treatments.

Exon-skipping drug development

• ▪Entrada Therapeutics is one of a group of companies developing new exon-skipping drugs for Duchenne muscular dystrophy.
• ▪Exon-skipping drugs are designed to help patients with certain mutations produce shortened but still functional forms of dystrophin.
• ▪Scientists have devised ways of redesigning exon-skipping molecules to better infiltrate muscle cells, leading to vastly higher dystrophin levels.

Sarepta approval history

• ▪Sarepta Therapeutics' first exon-skipping drug was approved in 2016 under immense pressure from patient advocates.
• ▪Sarepta Therapeutics' first exon-skipping drug had only marginal effects on protein production.
• ▪Dystrophin is the protein missing in Duchenne muscular dystrophy.
• ▪Sarepta Therapeutics developed the first exon-skipping drug for Duchenne muscular dystrophy.

1 source